Press release
Plaque Psoriasis Clinical Trial Pipeline Experiences Rapid Expansion as Over 75+ Leading Companies Advance Novel Therapies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Plaque Psoriasis Treatment Landscape. Click here to read more @ Plaque Psoriasis Pipeline Outlook [https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Plaque Psoriasis Pipeline Report
* In July 2025, Janssen Research & Development LLC announced a study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
* In July 2025, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. Ltd conducted a Phase II Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamic (PD) Profile of TQH3906 in Subjects With Moderate to Severe Plaque Psoriasis
* DelveInsight's Plaque Psoriasis pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Plaque Psoriasis treatment.
* The leading Plaque Psoriasis Companies such as Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics and others.
* Promising Plaque Psoriasis Therapies such as EDP1815, AX-158, RWJ-445380, Tapinarof cream, 1%, Bimekizumab, TAK-279 and others.
Discover groundbreaking developments in Plaque Psoriasis therapies! Gain in-depth knowledge of key Plaque Psoriasis clinical trials, emerging drugs, and market opportunities @ Plaque Psoriasis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Plaque Psoriasis Emerging Drugs Profile
* ARQ-151: Arcutis Biotherapeutics
Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase-4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases the production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the systemic treatment of plaque psoriasis and the topical treatment of atopic dermatitis. Topical roflumilast cream is a highly potent, selective PDE4 inhibitor in a convenient, once-daily formulation that Arcutis is developing for chronic plaque psoriasis and atopic dermatitis.
* ABY-035: Affibody
ABY-035 is a novel bispecific agent, potently targeting both subunits of IL-17A as well as albumin. ABY-035 has been specifically designed to utilize the strengths of Affibody's technology platform to create a very small protein drug (18 kDa, an eighth of the size of an antibody) with very high apparent affinity to IL-17A (KD ~300fM) and antibody-like half-life due to the strong (KD ~50pM) binding affinity to serum albumin.
* AK101: Akeso Biopharma
AK101 injection is a novel antibody drug developed independently by the Company under the National Major Innovative Drug Projects. It is intended to be used for the treatment of autoimmune diseases such as psoriasis, Crohn's disease, ulcerative colitis and lupus. AK101 clinically treats autoimmune diseases by blocking the biological activities of cytokines IL-12 and IL-23. Johnson & Johnson's Ustekinumab (trade name: Stelara) which has the same drug targets has been approved by the FDA for the treatment of psoriasis, Crohn's disease, and ulcerative colitis, and yielded US$6.4 billion in sales in 2019. Currently, it is in Phase III stage of clinical trial evaluation to treat Plaque Psoriasis
The Plaque Psoriasis pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Plaque Psoriasis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Plaque Psoriasis Treatment.
* Plaque Psoriasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Plaque Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Plaque Psoriasis market.
Stay informed about the Plaque Psoriasis pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Plaque Psoriasis Unmet Needs [https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Plaque Psoriasis Companies
Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics and others.
Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous
Plaque Psoriasis Products have been categorized under various Molecule types such as
* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine
Transform your understanding of the Plaque Psoriasis Pipeline! See the latest progress in drug development and clinical research @ Plaque Psoriasis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Plaque Psoriasis Pipeline Report
* Coverage- Global
* Plaque Psoriasis Companies:- Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutic s and others.
* Plaque Psoriasis Therapies- EDP1815, AX-158, RWJ-445380, Tapinarof cream, 1%, Bimekizumab, TAK-279 and others.
* Plaque Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Plaque Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Immunological and Autoimmune Disorders Research-Access the Full Plaque Psoriasis Pipeline Analysis Today! @ Plaque Psoriasis Drugs and Companies [https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Plaque Psoriasis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Plaque Psoriasis - DelveInsight's Analytical Perspective
* Late Stage Products (Preregistration)
* ARQ-151: Arcutis Biotherapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ABY-035: Affibody
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* CT303: GC Cell
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Plaque Psoriasis Key Companies
* Plaque Psoriasis Key Products
* Plaque Psoriasis- Unmet Needs
* Plaque Psoriasis- Market Drivers and Barriers
* Plaque Psoriasis- Future Perspectives and Conclusion
* Plaque Psoriasis Analyst Views
* Plaque Psoriasis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=plaque-psoriasis-clinical-trial-pipeline-experiences-rapid-expansion-as-over-75-leading-companies-advance-novel-therapies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/plaque-psoriasis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Plaque Psoriasis Clinical Trial Pipeline Experiences Rapid Expansion as Over 75+ Leading Companies Advance Novel Therapies here
News-ID: 4117206 • Views: …
More Releases from ABNewswire
Top 6 Deck Builders In Kansas City For Stunning Outdoor Spaces
Outdoor living has evolved to become something more.
It is now a lifestyle choice.
Today's families seek spaces that harmonize with the natural world, yet remain as comfortable and well-designed as rooms in their homes. Patios and pergolas aren't an afterthought, but an absolute must that adds significant value to your property and makes everyday life better.
In areas with seasonal weather, where people can be outside for most of the year, homeowners…
Dash Capital Expands Zero Interest Business Loans in Detroit Following Unprecede …
Dash Capital's expansion in Detroit reflects strong demand from local businesses for flexible, fast funding solutions that support growth and operational needs across the Motor City's diverse economic landscape.
The Detroit business landscape continues to show remarkable resilience and growth potential, prompting Dash Capital to expand its funding programs in response to overwhelming demand from local entrepreneurs. This expansion comes at a time when Motor City businesses are actively seeking alternative…
Jacksonville Family Business Expands Concrete Washing Services Amid Growing Prop …
Nubirth Pressure Washing, a family-owned company serving Jacksonville since 2004, reflects the growing demand for specialized exterior property cleaning in Northeast Florida, offering comprehensive surface restoration services.
Jacksonville, FL - The Northeast Florida property maintenance industry has witnessed significant growth in specialized cleaning services as homeowners and businesses prioritize exterior property care. Local family-owned company Nubirth Pressure Washing [https://www.google.com/maps/place/Nubirth+Pressure+Washing/@30.3340387,-81.7122184,17z/data=!3m1!4b1!4m6!3m5!1s0x88e5b9c01d715555:0xd2c2470a4640f2be!8m2!3d30.3340387!4d-81.7122184!16s%2Fg%2F11vk2l_v57!5m1!1e3?entry=ttu&g_ep=EgoyMDI1MDgyNS4wIKXMDSoASAFQAw%3D%3D] represents this trend, having served the Jacksonville area since 2004 with comprehensive…
A-Class Moving & Storage Expands Direct Delivery Network, Positioning Miramar Mo …
A-Class Moving & Storage, based in Miramar, has expanded its direct delivery network across South Florida, strengthening its position as a leading moving company and reliable alternative to traditional van line brokers. The growth allows the family-owned business to serve more customers while preserving its personalized service standards.
A-Class Moving & Storage has announced a significant expansion of its direct delivery network throughout South Florida, establishing the business as a leading…
More Releases for Plaque
Plaque Psoriasis Market Detailed Industry Report Analysis 2025-2034
Introduction
Plaque psoriasis is the most common type of psoriasis, accounting for nearly 80-90% of all cases worldwide. It is a chronic autoimmune skin disorder characterized by red, inflamed, and scaly plaques that significantly impair physical comfort, social interactions, and emotional well-being.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71345
Historically, treatments included topical corticosteroids, phototherapy, and systemic drugs. However, the market has been reshaped by the arrival of biologics, JAK/TYK2…
Best Plaque Removers: 2024 Ultimate Guide Released
With dental health becoming increasingly important to consumers, Verified Review Pro (https://www.verifiedreviewpro.com/best-plaque-tartar-removers/) has released their comprehensive analysis of the best plaque removers for 2024. This extensive guide arrives at a crucial time when more people are seeking effective home dental care solutions.
"The market for the best plaque removers has evolved significantly in recent years," explains Sarah Harrington, Lead Product Analyst at Verified Review Pro. "Our research shows that 78% of…
SWISSKLIP PLAQUE BLASTER REVIEWS 2023:DON'T BE FOOLED!IS SWISSKLIP PLAQUE BLASTE …
Swissklip Plaque Blaster has been making waves in the dental hygiene market, gaining popularity and acclaim in the United States for its proven effectiveness in removing plaque. This innovative device has become a go-to solution for individuals seeking a reliable and efficient way to maintain optimal oral health. In this comprehensive Swissklip Plaque Blaster review, we will delve into the features, benefits, and overall worthiness of this product, giving you…
Plaque Psoriasis Market Report, History and Forecast 2023-2031
Plaque Psoriasis Market 2023 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Plaque Psoriasis industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2023 to 2031 time period. It presents a close overview…
Plaque Psoriasis Global Manufacturers Market by Valuates Reports
Latest Updates on Psoriasis market research
Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin. These skin patches are typically red, dry, itchy, and scaly.
Emerging Phase III products for Plaque Psoriasis
This report provides a comprehensive understanding of the emerging Phase III therapies for Plaque Psoriasis which can turn out to be future prospective competitors for the marketed products. It will also put light on the current…
Global Plaque Modification Devices Market Trend and Forecast 2025
This study focuses on the production side and consumption side of Plaque Modification Devices, presents the global Plaque Modification Devices market size by manufacturers, regions, type and application, history breakdown data from 2013 to 2018, and forecast to 2025.
In terms of production side, this report researches the Plaque Modification Devices capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and product type.
In terms of…
